Planisware Briefing Note
Axendia was briefed by Aimee Rodrigues, VP, Life Sciences; Jean Pascal Casagrande, VP Product Strategy and Growth; and Ugbad Farah, Director of Analyst Relations, at Planisware.
Our discussion focused on how the company is positioning strategic portfolio management for a life sciences market under growing pressure to improve speed, reduce inefficiency, and make more defensible decisions across increasingly complex product lifecycles.
The conversation moved beyond conventional portfolio visibility into forecasting, risk, scenario modeling, capacity management, and explainable AI. It also raised a broader question that is becoming more relevant across the sector: how can life sciences companies extend strategic portfolio management across the product lifecycle?
Industry Context
As margin pressures rise, organizations are being asked to make faster decisions with greater confidence. This is one reason the industry is moving beyond static systems of record toward systems of action that can support intervention, simulation, and more continuous forms of decision support. That shift has become especially important in environments where the cost of delay, misallocation, or fragmented visibility is no longer tolerable.
According to Farah “Planisware is focused on closing the gap between strategy and execution by helping our customers ensure that their decisions, investments, and delivery remain continuously aligned as their priorities change.” Against that backdrop, she emphasized Planisware’s strategic planning, resource and cost management, scenario analysis, and analytics as part of a unified platform for enterprise execution.
The issue is no longer whether organizations can track work. The issue is whether they can connect portfolio intent to operational action in time to matter.
Programs in life sciences routinely span many years and involve teams across research, development, regulatory, quality, manufacturing, finance, and commercialization. Yet the supporting data often remains distributed across point solutions that serve local needs while leaving leadership without an integrated planning model.
Rodrigues described that planning reality directly when she said, “Pharma projects are not one- and two-year programs,” and asked, “What does the future look like for our organization? How do we make sure that we have the people to do it and that we have the budget?” Her point underscores that long-horizon planning is not simply a PMO function. It is a strategic discipline.
Portfolio Planning in a Long Horizon Industry
Much of Planisware’s solutions center on multi-level planning, parametric estimation, probability of technical and regulatory success, and what-if scenario analysis for highly regulated and uncertain development environments.
Rodrigues said the platform supports “ advanced multi-level planning so that functional child plans can stay synchronized to a broader parent program.” That matters because it addresses a common weakness in fragmented planning environments, where each function manages its own view of progress while leadership still needs a coherent picture of portfolio exposure, timing, and demand.
Risk Management as an Operational Discipline
The discussion moved beyond generic risk management capability claims. Rodrigues said Planisware aims to serve as a system of record for risk while drawing a clear boundary around patient data that should remain in systems such as CTMS. That distinction matters because life science organizations must connect risk signals, mitigation activities, lessons learned, and program implications across product lifecycle phases and functional areas.
Rodrigues also noted that many risk registers remain in repositories that are rarely reused, even when later programs could benefit from that experience. Her point reflects a broader industry issue: risk intelligence is often captured but not operationalized. The opportunity is to make it actionable across the lifecycle rather than archival at the end of a project.
Explainable AI in Regulated Environments
The AI discussion was notable because it avoided the overstatement that often surrounds enterprise AI. Casagrande emphasized that established analytical methods such as Monte Carlo simulation and sensitivity analysis are regaining importance because AI on its own can be unpredictable. He said the goal is not to pull “a result out from a magician’s hat” but to produce something “explainable and repeatable.”
In regulated environments, the question is not whether AI can generate an answer. It is whether the answer can be trusted, challenged, and justified. Casagrande described an approach in which AI augments existing analytical techniques, helps users run simulations, interprets results, and retrieves relevant historical patterns while keeping the reasoning grounded in a more inspectable framework.
That emphasis on explainability aligns with wider concerns Axendia continues to see across the sector. As AI moves deeper into planning, forecasting, and operational decision support, organizations will need more than productivity gains. They will need traceability, confidence, and a way to demonstrate why a recommendation was accepted or challenged.
Casagrande also said the company’s natural-language querying model under development is designed to show exactly which table and field the system is using, providing what he described as “full traceability and explainability of the answer.”
This level of transparency becomes increasingly important as AI-enabled tools are used in settings where auditability and retrospective scrutiny are part of normal operating reality. In this respect, the company’s approach appears less focused on AI as spectacle and more focused on AI as governed decision infrastructure.
Extending the Platform Across the Product Lifecycle
The larger strategic question for Planisware may be how far it can extend this logic across the product lifecycle. The briefing suggested that the company’s capabilities may resonate beyond traditional PMO and portfolio audiences. The discussion touched on manufacturing scale-up, equipment and facility capacity, product lifecycle risk, engineering collaboration, and the financial impact of delays.
It also highlighted a recurring commercial challenge. Strong capabilities do not always gain traction if they are framed in language that maps to one constituency but not another. What Planisware describes as bottleneck analysis may align closely with what manufacturing or operations leaders understand as advanced planning and scheduling or resource leveling. That may sound like a semantic issue, but it is more than that. Language shapes whether a solution is recognized as relevant to an operational problem.
Staging a Platform for Maturity and Growth
Planisware’s platform strategy reflects a broader ambition. According to Rodrigues, “Planisware Orchestra and Planisware Enterprise now sit on the same platform backbone, allowing organizations to begin with a more contained environment and expand as needs mature.” Planisware Orchestra is positioned as the company’s entry-level turnkey project portfolio management environment for PMOs, while Planisware Enterprise is positioned as an enterprise-scale platform connecting budgets, forecasts, schedules, resources, and actuals. For life science organizations with uneven process and technology maturity across business units, that scalability is significant. It offers a path that begins with project discipline but can evolve into broader execution governance across product lifecycle stages and functions over time.
In Brief
Planisware highlighted how strategic portfolio management, long-range planning, risk visibility, and explainable AI can support life sciences organizations operating under increasing financial, operational, and regulatory constraints. The most compelling parts of the discussion were not the feature lists, but the places where the company connected those capabilities to pressing industry realities such as resource scarcity, fragmented planning, lifecycle risk, and the need to make decisions that can be justified under scrutiny.
The opportunity ahead is not simply to reinforce value for portfolio and PMO stakeholders. It is to extend that value into R&D, clinical, scaleup, manufacturing, supply chains and broader lifecycle execution.
In a market that increasingly rewards connected planning, managed risk, and governed action, that evolution may matter as much as the technology itself.
We will continue to monitor how Planisware develops this position across the product lifecycle.
Ready to unlock new opportunities and drive success? Schedule an Analyst Inquiry
Stay Connected with Axendia!
Stay at the forefront of innovation and technology in life sciences, healthcare, and space-enabled research by connecting with Axendia.
- Follow us on LinkedIn: Join our professional network and stay updated on the latest insights, trends, and case studies. Connect with Axendia on LinkedIn
- Subscribe to Our Updates: Get exclusive insights and thought leadership articles delivered straight to your inbox. Sign up for our newsletter
- Share Your Thoughts: We’d love to hear from you! Contact us to discuss your ideas, challenges, or opportunities. Email Axendia
Let’s drive innovation together!
The opinions and analysis expressed in this post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this post is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This post is not intended to endorse any company or product and should not be attributed as such.